Hogan Lovells (Washington)

Robert (Bob) F. Leibenluft

Hogan Lovells (Washington)
Senior Counsel

Bob Leibenluft’s antitrust practice is unusual in that it focuses on only one industry – health care and life sciences – yet it spans all industry sectors, including providers, payers, and drug and device manufacturers. He brings over 35 years of experience, including heading the FTC Health Care Division, to his representation of clients in counseling, investigations, transactions, and litigation matters. Starting at the firm in 1981 as a health regulatory lawyer, Bob became a nationally recognized lawyer on Medicare issues. His deep understanding of the industry was a reason he was asked to lead the FTC Health Care Division in the mid-1990s, where he supervised drafting of the FTC/DOJ Health Policy Statements, which first addressed clinical integration, and led investigations of hospital mergers and physician networks. On a pro bono basis, Bob has led a 10-year review of the D.C. government’s response to HIV/AIDs, advised the government of Liberia on a new public health law, and provided antitrust advice to the CEO Roundtable on Cancer. Chambers USA describes Bob as "renowned for his expertise in health care antitrust and is singled out by a source as someone who really knows how the system works" and who is hailed by peers as a "terrific health care antitrust lawyer." Bob is an inaugural fellow and former vice president of the American Health Lawyers Association. He is a former Chair of the ABA Antitrust Section’s Health and Pharmaceuticals Committee, Joint Conduct Committee, and State Enforcement Committee. Bob also served as Chair of the Board of Directors of HCI3, the parent of Prometheus Payment, and Bridges-to-Excellence. He teaches the course Antitrust in the Health Care Sector at George Washington School of Law, where he is an adjunct professor.

Linked authors

Hogan Lovells (Madrid)
Hogan Lovells (London)
Hogan Lovells (London)
Hogan Lovells (Washington)
Hogan Lovells (Washington)


1263 Bulletin

Robert (Bob) F. Leibenluft, Jonathan Elsasser, Justin W. Bernick, Chuck Loughlin, William F. Ferreira The US FTC proposes to ban employer non-compete agreements which signals a possible sea-change for employers across industries


The Federal Trade Commission’s (FTC’s) January 5, 2023 Notice of Proposed Rulemaking (NPRM) for the Non-Compete Clause Rule, which would ban nearly all post-employment non-competes, signals a possible sea-change for employers across industries. Significantly, however, non-profit (...)

Jonathan Elsasser, Robert (Bob) F. Leibenluft, Ilana Kattan The US FTC seeks to block another two hospital mergers following recent successes and growing concerns over increased concentration in the hospitals sector (HCA Healthcare / Steward Health Care System) (RWJ Barnabas Health / Saint Peter’s Healthcare System)


On the heels of two successful hospital merger challenges in the last year, the FTC announced on Thursday that it is bringing two new cases seeking to block proposed hospital transactions: RWJBarnabas Health’s (RWJ’s) acquisition of Saint Peter’s Healthcare System (Saint Peter’s) in New Jersey (...)

Robert (Bob) F. Leibenluft, Leigh Oliver, Jonathan Elsasser The US FTC initiates proceedings against two hospitals to prevent their proposed merger (Hackensack Meridian Health / Englewood Healthcare)


On 4 August 2021, the District Court of New Jersey granted the Federal Trade Commission’s (FTC) motion for preliminary injunction, preventing Hackensack Meridian Health (HMH) and Englewood Healthcare (Englewood) from closing their proposed merger pending an administrative trial before an FTC (...)


Total visits

Number of readings per contribution

Number of contributions

Author's ranking
In number of contributions
In number of visits
In average number of visits
Send a message